Author L. Rea has lived his entire life by this motto, and he knew in 2001 that the time had to come to apply the knowledge he had learned from a lifetime spent in bodybuilding and research to a new purpose. ALR Industries was born to provide those who refuse to accept mediocrity the tools to reach their full potential. Author L. Rea is not only a bodybuilder himself, but also one of the scientists behind the development of all the ALR Industries products. His combined experience of more than three decades in the worlds of bodybuilding, and biological research and development, has lead to some of the most inventive and effective supplements for bodybuilding, health, and fitness ever created. As the author of three books and 100’s of article on human performance and health, Author L. Rea has shared his passion for never accepting mediocrity with the world. Chemical Muscle Enhancement References:

Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma.  If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease.  Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids.  Edema may occur occasionally with or without congestive heart failure.  Concomitant administration of adrenal steroids or ACTH may add to the edema.  In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth.  This adverse effect may result in compromised adult stature.  The younger the child the greater the risk of compromising final mature height.   The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.  This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.

When one compares the fast-acting 17-alpha alkylated oral version of 4-OHN (Methyl-4-hydroxynandrolone) to methyltestosterone (17-alpha-methyl-testosterone), you realize that it possesses a myotrophic (muscle building action) that is about 27 times higher than that of the well know oral AAS methyltestosterone. (Pretty cool, huh?) It also possesses androgenic properties that are over 5 times higher than methyltestosterone. However if we compare a long-chain injectable ester (4-OHN cypionate or decanoate) with prolonged release, you will find that it possesses much greater myotrophic action than testosterone cypionate…but with no androgenic properties. This is a fairly common pharmacokinetic difference between fast-acting orals and slow acting injectables. Different release patterns, alkylation or esterfication as well as metabolism dramatically alter physiological effects of the same base prosteroid.